Download our presentation from Recovery of Biological Products XX titled “Turning the crank using a hybrid continuous purification platform” from Michelle Najera, Megan McClure, Shahbaz Gardezi and Beth Larimore.
Learn how:
- Process intensification solutions for monoclonal antibodies, Fc-fusion proteins and bispecific antibodies t ease liquid handling pain points.
- Our J.CHOTM High Expression System is delivering perfusion permeate titers of over 2 g/L/d over 25 days.
- Continuous capture chromatography significantly enhances resin utilization
- Two tank virus inactivation steps can be developed with bench-scale models
Download the Presentation
Tags:
Oncology,
Presentations,
Formulation & CMC,
Biologics,
IND Enabling Studies/Preclinical Development,
Immunology & Inflammation,
Rare Diseases
Continuous biomanufacturing is reducing the cost of goods of biopharmaceuticals. Achieving continuous manufacturing requires expertise in equipment design.
Download the highlights of Andrea Isby's presentation at Repligen's DSP Workshop in Estonia from May 23rd, 2024 to learn more.
Download the presentation
Tags:
Neuroscience,
Respiratory,
Oncology,
Kidney diseases,
Women's health,
Presentations,
Blog,
Formulation & CMC,
Biologics,
Age-Related Diseases,
IND Enabling Studies/Preclinical Development,
Anti-Infectives,
Immunology & Inflammation,
Metabolic Disease & Complications,
Rare Diseases,
Clinical Development
Download the highlights from our DCAT presentation to learn how continuous biomanufacturing reduces the environmental impact of antibody production.
The continuous manufacturing of therapeutic antibodies in agile facilities with a small cleanroom footprint allows:
- 67% reduction in facility footprint
- 50% less process water
- 65% less plastic waste
- 73% lower CO2 emissions
Just-Evotec Biologic's unique continuous biomanufacturing platform for antibody therapeutics and innovative J.POD facility design are reducing manufacturing costs and increasing the sustainability of bioproduction.
View the presentation to learn more!
Download the Presentation
Tags:
Presentations,
Formulation & CMC,
Biologics
Just-Evotec Biologics’ continuous manufacturing platform is enabled by a range of innovative technological solutions. Magnus Schroeder, VP Process & Product Design described the technology advances that we have applied to allow fully continuous downstream processing at BPI West San Diego.
These include:
• Key enables of continuous process technology
• Custom skid designs for continuous operations
• Dynamic modelling approach for CM
• Continuous viral filtration
For a more detailed discussion contact us at: info@evotec.com
Download Some of the Highlights of his Presentation Here
Tags:
Presentations,
Biologics
Presentation slide deck for the webinar Deciphering the Clinincal DDI Between Atazanavir and Rosuvastatin.
Tags:
Presentations,
ADME/DMPK
Thermostability assays (DSF) are one of the workhorses of biochemistry and structural biology. Thanks to the simplicity of the assay setup they found wide applications in many fields. To meet the high demand in DSF assays from our clients, Evotec established DSF pipelines in all five of the sites that offer biophysics services. We find that thermostability assays are highly useful for hit validation & expansion, however, can be also used to reveal the mode of action of the candidate molecule.
In this presentation we:
- Describe how we use thermal unfolding assays (DSF) to support drug discovery
- Discuss the cases when model-based analysis reveals in-depth information about the drug/target interaction
- Share the perspectives on combing high-throughput and high-content approaches
This talk was presented at MOSBRI Workshop "Pushing the limits with Differential Scanning Fluorimetry" on 16 November 2022.
Tags:
Presentations,
Hit & Target ID/Validation,
Structural Biology & Protein Science
About the Webinar
This is a recorded live presentation given by Thierry Wurch, PhD - Senior VP, Integrated Biologics Discovery at Evotec during the Antibody Engineering and Therapeutics Europe (AE&T) conference in Amsterdam, June 2022.
Content Summary:
- At Evotec we discover, develop and manufacture novel medicines for hard-to-treat diseases through efficient partnerships with academia, biotechs and pharma
- For antibody-based modalities, Evotec has developed an integrated discovery platform ranging from target validation, antibody discovery and optimization, in vitro/in vivo pharmacology, PK, and toxicology to select the best clinical candidates
- We apply both humanized, mouse-derived hybridoma and phage display (from immune and synthetic antibody libraries) coupled to automated HTS antibody screening and AI/ML-based optimization, antibody hits are selected to best fit their intended modality, (e.g. mAbs, ADCs, bispecifics)
- A particular emphasis is placed on integrating good manufacturing properties for the selected antibody sequence
About the Speaker
 |
Thierry Wurch
SVP, Integrated Biologics Discovery | Evotec
Thierry joined Evotec in May 2022 as SVP Integrated Biologics Discovery. He has more than 22 years of expertise in the antibody R&D space primarily in Oncology and immune-oncology. Thierry held positions of growing strategic importance from head of an antibody discovery and engineering department (Pierre Fabre, 2003-2011), head of immunotherapy discovery research activities (Servier, 2011-2017) then moving to BD-oriented activities and heading external innovation for Oncology (Servier, 2017-2020 and Ipsen 2020-2022). Thierry is also Chairman of the antibody sub-committee at NC-IUPHAR, member of the Editorial board of mAbs Journal and Distinguished Advisor of The Antibody Society.
|
[hs-form id="052874a9-75e5-4960-9b82-931f9dd753b7" show="hide on login" url="https://player.vimeo.com/video/719092289"]
Tags:
Presentations,
Videos & Webinars,
Biologics
Interesed in Evotec's Translational Molecular Patient Database?
In this presentation, first presented at our luncheon during German Biotechnology Days, focuses on:
- The database's over 200,000 samples and data from over 15,000 patients
- Data-driven approaches for better diagnoses
- Categorization by disease mechanisms
View the presentation to learn more!
LEARN MORE
Tags:
Presentations,
Proteomics, Metabolomics & Biomarkers
Learn more about Multi-Omic Analysis of Induced Biotherapeutic Protein Production in CHO Cells Reveals Substantial Shifts in Energy Allocation in this presentation from PEGS Boston - Optimizing Protein Expression from May 2021.
In this presentation, we focus on:
- Experimental design
- Data processing and analysis in transcriptomics
- Multivariate 'omic analysis
- CHO clone screenings
Tags:
Presentations,
Biologics
